Morgan Stanley keeps an Overweight rating and $10 price target on LifeStance with a “positive catalyst” call on the stock ahead of earnings. The firm expects the company to deliver revenue upside in Q3 and guide above for Q4, and with 2023 being characterized as a year of investment in the business, the analyst is looking for additional anecdotes on operational improvements, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LFST:
- Morgan Stanley sees ‘compelling entry point’ after LifeStance targeted by shorts
- LifeStance ‘represents the worst of the public markets,’ says The Bear Cave
- LifeStance to Host Third Quarter 2023 Earnings Conference Call on November 8, 2023
- LifeStance to Present at the 7th Annual Bernstein Healthcare Services Disruptors Conference
- LifeStance to Present at the 21st Annual Morgan Stanley Healthcare Conference